PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 5 | 3 | A117-121
Article title

Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review

Content
Title variants
Languages of publication
EN
Abstracts
EN
We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurred in the form of a drug-induced interstitial lung disease. We also provide a review of the literature concerning opinions on incidence, clinical picture, consequences and management of the complication discussed.
Discipline
Publisher
Journal
Year
Volume
5
Issue
3
Pages
A117-121
Physical description
References
  • 1. Summary of Product Characteristics AFINITOR. [ online: www.ema.europa.eu/docs/pl_PL/document.../WC500022814.pdf].
  • 2. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47(9): 1287-98.
  • 3. Saito Y, Kunugi S, Suzuki Y et al. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy. Intern Med 2013; 52(2): 263-7.
  • 4. Akata K, Yatera K, Ishimoto H et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011; 50(24): 3013-7.
  • 5. Baas MC, Struijk GH, Moes DJ et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014; 27(5): 428-36.
  • 6. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010; 137(2): 456-9.
  • 7. Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-80.
  • 8. Iacovelli R, Palazzo A, Mezi S et al. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51(7): 873-9.
  • 9. Nozawa M, Nonomura N, Ueda T et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol 2013; 43(11): 1132-8.
  • 10. Park K, Lee JL, Ahn JH et al. Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Cancer Res Treat 2014; 46(4): 339-47.
  • 11. White DA, Camus P, Endo M et al.: Non-infectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
  • 12. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-56.
  • 13. Park K, Kim HJ, Lee JL et al. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Res 2014; 34(10): 5723-8.
  • 14. Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012; 104(2): 93-113.
  • 15. Grünwald V, Weikert S, Pavel ME et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013; 36(5): 295-302.
  • 16. Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A et al. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012; 31 Suppl 1: S19-27.
  • 17. Willemsen AE, De Vos FY, Jansen A et al. Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol 2014; 9(3): 287-91.
  • 18. Saito Y, Nagayama M, Miura Y et al. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol 2013; 43(5): 559-62.
  • 19. Kubo K, Azuma A, Kanazawa M et al: Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Resp Investigation 2013; 51: 260-277.
  • 20. Dabydeen DA, Jagannathan JP, Ramaiya N et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48(10): 1519-24.
  • 21. Atkinson BJ, Cauley DH, Ng C et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014; 113(3): 376-82.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-5c25e917-28c6-44c4-9e70-f018249d31cf
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.